ReviewClinical kidney journal2023
Expanded hemodialysis: what's up, Doc?
Review in Clinical kidney journal, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Trial
- Review
- Budget impact of expanded hemodialysis versus high-flux hemodialysis using real-world evidence in Colombia.Cost effectiveness and resource allocation : C/E · 2026Article
- Expanded Hemodialysis Using a Medium Cut-Off Dialyzer for Severe Valproic Acid Poisoning: A Case Report with Real-Time Therapeutic Drug Monitoring.Journal of clinical medicine · 2026Article
- Clinical benefits and future directions of medium cut-off membranes in hemodialysis: a comprehensive review.The Korean journal of internal medicine · 2025Review
- Do Medium Cut-Off Dialyzers Offer Any Clinical Benefit or Should We Focus on Hemodiafiltration?Journal of the American Society of Nephrology : JASN · 2025Article
- Efficacy of Expanded Hemodialysis and Comparison with Standard Hemodialysis and Online Hemodiafiltration.International journal of molecular sciences · 2025Article
- Effects of super high-flux vitamin E-coated and medium cut-off dialyzers on uremic toxins removal and biocompatibility: the E-FLUX randomized controlled study.Clinical kidney journal · 2025Article
- Green, Sustainable Nephrology: State of the Art Needs for Education and Implementation.Clinical journal of the American Society of Nephrology : CJASN · 2025Review
- Article
- Survival Differences in Patients with High-Flux Hemodialysis versus Expanded Hemodialysis: A Cohort Study.Blood purification · 2025Article
- Efficacy in the reduction ratios of middle molecules with the use of medium cut-off dialyzers and reduced dialysate flows: a cohort study.Frontiers in medicine · 2025Article
- Medium cut-off membrane expanded hemodialysis for Lithium removal: a case report.Frontiers in toxicology · 2025Article
- Technical requirements and devices available for long-term hemodialysis in children-mind the gap!Pediatric nephrology (Berlin, Germany) · 2024Review
- Article
- Differences in drug removal between standard high-flux and medium cut-off dialyzers in a case of severe vancomycin toxicity.Clinical kidney journal · 2024Article
- Latest Trends in Hemodiafiltration.Journal of clinical medicine · 2024Review
- Expanded Hemodialysis ameliorates uremia-induced impairment of vasculoprotective KLF2 and concomitant proinflammatory priming of endothelial cells through an ERK/AP1/cFOS-dependent mechanism.Frontiers in immunology · 2023Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In recent years there has been an increasing interest in expanded hemodialysis (HDx), an emerging renal replacement therapy based on the use of medium cut-off membranes (MCO). Thanks to the internal architecture of these types of membranes, with a higher pore size and smaller fiber inner diameter to favor internal filtration rate, they can increase the removal of larger middle molecules in conventional hemodialysis. Secondarily, several reports suggest that this therapy potentially improve the outcomes for end-stage renal disease patients. However, HDx has not been defined yet and the characteristics of MCO membranes are not well stablished. The aim of this narrative review is to define HDx and summarize the dialyzers that have been used so far to perform this therapy, collect the evidence available on its efficacy and clinical outcomes compared with other hemodialysis techniques and settle the bases for its optimal prescription.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.